Septerna (NASDAQ:SEPN) Reaches New 12-Month High – Time to Buy?

Septerna, Inc. (NASDAQ:SEPN) shares hit a new 52-week high on Thursday . The company traded as high as $38.04 and last traded at $37.7610, with a volume of 462037 shares changing hands. The stock had previously closed at $36.40.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on SEPN. Truist Financial upped their target price on shares of Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Septerna in a research report on Wednesday, July 1st. Raymond James Financial upped their target price on Septerna from $47.00 to $53.00 and gave the stock a “strong-buy” rating in a report on Monday, June 8th. JPMorgan Chase & Co. increased their target price on shares of Septerna from $34.00 to $38.00 and gave the stock an “overweight” rating in a report on Tuesday, March 24th. Finally, Wall Street Zen lowered shares of Septerna from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Septerna has an average rating of “Moderate Buy” and a consensus price target of $45.89.

Septerna Stock Up 3.7%

The company has a market cap of $1.70 billion, a PE ratio of -46.69 and a beta of 2.29. The firm has a 50 day simple moving average of $30.68 and a 200-day simple moving average of $27.83.

Septerna (NASDAQ:SEPN) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.23. The business had revenue of $26.52 million for the quarter, compared to analysts’ expectations of $16.98 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. As a group, equities analysts anticipate that Septerna, Inc. will post -1.59 EPS for the current year.

Insider Transactions at Septerna

In other news, COO Elizabeth Bhatt sold 4,000 shares of the stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $24.34, for a total transaction of $97,360.00. Following the completion of the sale, the chief operating officer owned 174,209 shares in the company, valued at approximately $4,240,247.06. This represents a 2.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Samira Shaikhly sold 11,798 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $30.06, for a total value of $354,647.88. Following the transaction, the insider owned 793 shares in the company, valued at approximately $23,837.58. This trade represents a 93.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 48,494 shares of company stock valued at $1,566,751. Corporate insiders own 5.80% of the company’s stock.

Institutional Trading of Septerna

Several large investors have recently bought and sold shares of the stock. Group One Trading LLC raised its holdings in shares of Septerna by 111.8% in the fourth quarter. Group One Trading LLC now owns 944 shares of the company’s stock worth $26,000 after buying an additional 8,955 shares during the last quarter. Global Retirement Partners LLC purchased a new stake in shares of Septerna during the fourth quarter valued at $35,000. Russell Investments Group Ltd. acquired a new position in shares of Septerna in the 3rd quarter valued at $36,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Septerna in the 4th quarter valued at $53,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Septerna in the 4th quarter worth $61,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.